Regeneron Phase 2 Trial Shows Trevogrumab Prevents Muscle Loss During GLP-1 Weight Loss

By Reuters News

- Regeneron Pharmaceuticals, Inc. REGN.O:

  • PHASE 2 COURAGE TRIAL CONFIRMS TREVOGRUMAB PREVENTS LEAN MASS AND MUSCLE LOSS DURING GLP-1 RECEPTOR AGONIST-INDUCED WEIGHT LOSS

  • REGENERON PHARMACEUTICALS, - TREVOGRUMAB PREVENTS 70% OF MUSCLE LOSS ASSOCIATED WITH SEMAGLUTIDE TREATMENT

  • REGENERON PHARMACEUTICALS, - PLANS PHASE 2 TRIAL OF TREVOGRUMAB WITH GLP-1 THERAPIES IN OLDER ADULTS

  • REGENERON PHARMACEUTICALS, - LOWER DOSES OF TREVOGRUMAB WELL TOLERATED WITH 77% EXPERIENCING AT LEAST ONE ADVERSE EVENT

Further company coverage: REGN.O

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk